Reply to Simon, Shah et al, and Hartzema and Chen

Affiliations

Comment

Sarah M Bartsch et al. Clin Infect Dis. 2014 Feb.

. 2014 Feb;58(4):605-7.

doi: 10.1093/cid/cit775. Epub 2013 Dec 2.

¹ Public Health Computational and Operations Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

No abstract available

Comment on

Is fidaxomicin worth the cost? An economic analysis.
Bartsch SM, Umscheid CA, Fishman N, Lee BY. Bartsch SM, et al. Clin Infect Dis. 2013 Aug;57(4):555-61. doi: 10.1093/cid/cit346. Epub 2013 May 23. Clin Infect Dis. 2013. PMID: 23704121 Free PMC article.
An economic analysis: is fidaxomicin worth the cost?
Shah H, Doyle JJ, Belletti DA. Shah H, et al. Clin Infect Dis. 2014 Feb;58(4):603-4. doi: 10.1093/cid/cit773. Epub 2013 Dec 2. Clin Infect Dis. 2014. PMID: 24300041 Free PMC article. No abstract available.
Is fidaxomicin worth the cost? The verdict is still out!
Hartzema AG, Chen C. Hartzema AG, et al. Clin Infect Dis. 2014 Feb;58(4):604-5. doi: 10.1093/cid/cit774. Epub 2013 Dec 2. Clin Infect Dis. 2014. PMID: 24300046 No abstract available.